Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products.
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products, delivers fast, reliable absorption for pain relief plus the lifesaving b...
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PLx Pharma Inc. Provides VAZALORE Launch Update
Details : VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin.
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach.
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast platelet inhibition as compared to enteric-co...
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
Details : VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications.
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and a bioequivalence study data from a recently completed BE study. The submission for 81 mg dose provided for a new product ...
Brand Name : Vazalore
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Park West Asset Management
Deal Size : $8.0 million
Deal Type : Financing
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing
Details : This financing round will fund PLx Pharma's lead candidate, VAZALORE, through the final steps of the regulatory process.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Park West Asset Management
Deal Size : $8.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?